PAVmed enters at-the-market equity sales agreement for up to USD 9.4 million of stock

• PAVmed entered an at-the-market sales agreement with A.G.P./Alliance Global Partners to issue common stock from time to time.
• Program size set at USD 9.4 million under a prospectus supplement dated Sept. 9, 2026.
• Sales agent commission fixed at 3% of aggregate gross proceeds.
• Net proceeds earmarked for working capital, general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-042021), on September 10, 2026, and is solely responsible for the information contained therein.